|
Ramaswamy, Bhuvaneswari; Mrozek, Ewa; Kuebler, John Philip et al. (2011) Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Invest New Drugs 29:347-51
|
|
Shah, Manisha H; Varker, Kimberly A; Collamore, Minden et al. (2009) G3139 (Genasense) in patients with advanced merkel cell carcinoma. Am J Clin Oncol 32:174-9
|
|
Bekaii-Saab, Tanios S; Mortazavi, Amir; Hicks, Lee G et al. (2006) A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). Invest New Drugs 24:343-6
|
|
Shah, Manisha H; Young, Donn; Kindler, Hedy L et al. (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10:6111-8
|
|
Liu, Jing; Kraut, Eric H; Balcerzak, Stanley et al. (2002) Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemother Pharmacol 50:445-53
|
|
Snapka, R M; Gao, H; Grabowski, D R et al. (2001) Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. Biochem Biophys Res Commun 280:1155-60
|
|
Huang, K C; Gao, H; Yamasaki, E F et al. (2001) Topoisomerase II poisoning by ICRF-193. J Biol Chem 276:44488-94
|
|
Gao, H; Yamasaki, E F; Chan, K K et al. (2000) Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison. Cancer Res 60:5937-40
|
|
Nettikadan, S R; Furbee, C S; Muller, M T et al. (1998) Molecular structure of human topoisomerase II alpha revealed by atomic force microscopy. J Electron Microsc (Tokyo) 47:671-4
|
|
Subramanian, D; Rosenstein, B S; Muller, M T (1998) Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: possible relationship with DNA repair. Cancer Res 58:976-84
|
Showing the most recent 10 out of 15 publications
